Microcarrier Market Growth by 2024-2033 | Global Insight Services

• By Material Type: Collagen-based, Gelatin-based, Hyaluronic Acid-based, Polystyrene-based, Dextran-based, and Modified Polyvinyl Alcohol
• By Technology: Two-Dimensional, and Three-Dimensional
• By Application: Regenerative Medicine, Cultured Meat Production, Vaccine Production, Cell Therapy, Biologics Manufacturing, Stem Cell Research, and Tissue Engineering
• By Equipment: Bioreactors, Cell Culture Vessels, Centrifuges, Incubators, Cell Counters, Separation Systems, Storage Systems, and Processing Systems
• By Size of Microcarriers: Small (<1,000 µm), Medium (1,000–2,000 µm), and Large (>2,000 µm)
• By End-User: Biopharmaceutical Companies, Contract Research Organizations, and Academic and Research Institutes
• By Region:
• North America: Includes United States and Canada
• Europe: Includes United Kingdom, Germany, France, Spain, Italy, Netherlands, Sweden, Switzerland, Denmark, Finland, Russia, and the rest of Europe
• Asia-Pacific: Includes China, India, Japan, South Korea, Australia, Singapore, Indonesia, Taiwan, Malaysia, and the rest of Asia-Pacific
• Latin America: Includes Brazil, Mexico, Argentina, and the rest of Latin America
• Middle East and Africa: Includes Saudi Arabia, UAE, Egypt, Iran, Qatar, South Africa, and the rest of MEA

Request A Sample Of This Report –https://www.globalinsightservices.com/request-sample/GIS20943

Market Trends and Drivers

Growing popularity of biodegradable microcarriers for cell manufacturing

The limited availability of adult stem cells necessitates the development of cost-effective methods for their large-scale expansion ex vivo. Microcarriers, established tools in the biopharmaceutical industry, offer a solution by providing a vast surface area for adherent cell growth in stirred-tank bioreactors. However, conventional microcarriers pose a safety risk due to potential microparticle contamination in the final cell product, hindering their use in clinical trials and approved autologous stem cell therapies. Consequently, even in clinical settings, adult stem cells, like mesenchymal stem cells (MSCs), are often cultured in labor-intensive and poorly controlled two-dimensional tissue culture flasks.

The development of dissolvable or degradable microcarriers represents a significant leap forward in overcoming challenges associated with stem cell expansion. These novel microcarriers degrade in vivo or dissolve in vitro, eliminating the contamination risk associated with traditional microcarriers. This innovation paves the way for gentler cell harvesting methods that don’t rely on harsh enzymatic dissociation. Alternative methods could involve manipulating factors like pH, temperature, or biochemical changes in cell-adherent molecules, all while preserving cell viability and function. Depending on the degradation rate, cells grown on these dissolvable microcarriers can be harvested either by dissolving the carriers within the bioreactor or by directly implanting both cells and microcarriers at the site of injury. Studies have shown promising results with various dissolvable microcarrier platforms, including porous PLGA microcarriers for culturing human adipose stem cells.

Integration with 3D bioprinting

Bioprinting offers a revolutionary approach for fabricating living tissue constructs with customized architectures. This technology holds particular promise for generating complex tissues like osteochondral tissue, which features a zonal composition in the cartilage domain supported by subchondral bone. However, challenges remain in creating functional grafts of clinically relevant size. These challenges include incorporating cues for specific cell differentiation and generating sufficient cell numbers, which can be difficult to achieve with conventional cell culture techniques. A novel strategy for overcoming these limitations involves combining bioprinting with microcarrier technology. Microcarriers enable the large-scale expansion of cells while promoting the formation of multicellular aggregates and controlled cell phenotype. This study explores the potential of bioprinting cell-laden microcarriers for fabricating living tissue constructs.

The researchers utilized mesenchymal stromal cell (MSC)-laden polylactic acid (PLA) microcarriers, obtained via static culture or spinner flask expansion. These microcarriers were then encapsulated within a gelatin methacrylamide-gellan gum bioink. The study evaluated the printability of this composite material and demonstrated the feasibility of fabricating constructs with high cell concentration and viability. The successful application of microcarriers in bioprinting for tissue engineering signifies a potentially significant new market segment for the microcarrier industry. This approach could drive demand for microcarriers with specific properties tailored for bioprinting applications, such as biocompatible materials, controlled degradation rates, and surface modifications. The exploration of microcarriers for bioprinting represents a promising avenue for the microcarrier industry. As research in this field progresses, we can expect to see the development of specialized microcarriers that further enhance the capabilities of bioprinting for tissue engineering and regenerative medicine applications.

Customise This Report As Per Your Requirements –https://www.globalinsightservices.com/request-customization/GIS20943

Restraints & Challenges

High costs associated with cell biology research

The microcarrier market holds immense promise for advancements in cell therapy, tissue engineering, and other biopharmaceutical applications. However, a significant barrier to wider adoption lies in the high costs associated with cell biology research.

Academic research labs often operate on tight budgets, prioritizing cost-effective solutions for cell culture experiments. The initial investment in high-quality microcarriers, coupled with the potentially specialized equipment required for their use (e.g., bioreactors), can be a significant financial hurdle. This limited adoption in academic research hinders the broader exploration and development of microcarrier applications, which could ultimately benefit the entire market. Many novel cell therapies and tissue engineering approaches rely on efficient and scalable cell culture techniques. Microcarriers offer significant advantages in this regard, but the high upfront costs can slow down the translation of promising research findings into real-world applications. This delay in downstream development reduces the potential market size for microcarriers, as their full potential remains unrealized.

Biocompatibility and immunogenicity concerns

Despite the exciting potential of microcarriers for cell therapy and tissue engineering, their widespread adoption is hampered by lingering concerns regarding biocompatibility and immunogenicity. In the context of microcarriers for cell therapy and tissue engineering, biocompatibility refers to the ability of the microcarriers to coexist peacefully with the human body. It encompasses two main aspects – cytocompatibility and in vivo compatibility. Cytocompatibility refers to the compatibility of the microcarriers with the cells themselves. Ideally, the microcarriers shouldn’t harm, inhibit the growth, or alter the function of the cells they are intended to support. In vivo compatibility refers to the broader compatibility of the microcarriers within the body. They shouldn’t trigger an inflammatory response, be toxic to surrounding tissues, or leave behind harmful residues after cell harvest.

On the other hand, immunogenicity refers to the potential of the microcarriers to trigger an immune response in the body. The materials used to create the microcarriers might be recognized as foreign by the body’s immune system. This can lead to the activation of immune cells that attack and destroy the microcarriers. An ideal microcarrier would be non-immunogenic. This is crucial for the safety and efficacy of cell therapy.

COVID-19 Impact

Pre-COVID-19 Pandemic Scenario

The microcarrier market experienced steady growth in the pre-COVID era (2018-2019), driven by several key factors such as increasing prevalence of chronic diseases, rising demand for cell therapies and vaccines, and growing investments in the healthcare research infrastructure, particulary in developed markets of North America and Europe. Several established players such as Thermo Fisher Scientific, Merck KGaA, Corning Life Sciences, and GE Healthcare dominated the market in the pre-COVID era. Merck KGaA acquired MilliporeSigma in 2015 (pre-COVID) to broaden their microcarrier portfolio. Increased government funding and policy changes supported the development and commercialization of cell therapies, which in turn fueled demand for microcarriers. In 2018, the National Institutes of Health (NIH) in the US launched a $100 million initiative to support cell and gene therapy research. In 2019, the European Medicines Agency (EMA) provided new guidelines for the development and manufacturing of cell and gene therapies, creating a more streamlined regulatory pathway for cell therapy products using microcarriers

COVID-19 Pandemic Scenario

The COVID-19 pandemic has had a significant impact on the global microcarrier market, influencing both demand and supply dynamics across various industries. As the pandemic spread globally, disruptions to supply chains, restrictions on movement, and shifts in healthcare priorities have affected the microcarrier market in several ways. One notable impact of the COVID-19 pandemic on the microcarrier market is the increased demand for cell culture products and solutions, including microcarriers, driven by the urgent need for vaccine development and biopharmaceutical manufacturing. With the race to develop and produce COVID-19 vaccines, there has been a surge in demand for cell culture technologies to support vaccine production, including microcarriers used in the propagation of virus-infected cells. Additionally, the pandemic has highlighted the importance of cell culture technologies in pandemic preparedness and response efforts, further driving demand for microcarriers as essential tools in vaccine production and biomanufacturing. However, the COVID-19 pandemic has also posed challenges to the microcarrier market, particularly in terms of supply chain disruptions and manufacturing constraints. Restrictions on movement, border closures, and lockdown measures have disrupted global supply chains, leading to shortages of raw materials, components, and finished products used in microcarrier manufacturing. Delays in shipping, logistics, and customs clearance have further exacerbated supply chain challenges, affecting the availability and delivery of microcarrier products to customers worldwide. Moreover, manufacturing facilities faced operational challenges, including workforce shortages, production shutdowns, and health and safety regulations, impacting production capacity and product availability.

Post-COVID-19 Pandemic Scenario

The COVID-19 pandemic undoubtedly impacted the microcarrier market, but the overall growth trajectory remained positive. While cell therapy research continued, the immediate focus during the initial stages of the pandemic shifted towards. Microcarriers played a role in the rapid development and production of COVID-19 vaccines. Companies like Thermo Fisher Scientific supplied microcarriers for use in viral vector production for these vaccines. Companies like Pall Corporation are developing microcarriers like Cytodex that integrate seamlessly with automated cell culture systems, promoting efficiency in large-scale cell therapy manufacturing. Emerging microfluidic technologies for cell culture are creating a new niche for microcarriers designed for these platforms. For instance, companies like XCell Biosciences are developing microfluidic bioreactors compatible with specific microcarriers. In 2021, the US Food and Drug Administration (FDA) approved the first gene therapy for ALS (Amyotrophic Lateral Sclerosis), demonstrating progress in regulatory pathways for cell and gene therapies using microcarriers.

Key Market Players

The microcarrier market report includes players such as Thermo Fisher Scientific, Merck KGaA, Sartorius AG, Corning Incorporated, Lonza Group, GE Healthcare, Eppendorf AG, HiMedia Laboratories, Incyte Corporation, Kuraray, Bio-Rad Laboratories, Takara Bio, Polysciences Inc., Novozymes, PromoCell GmbH, TCB, Teijin Ltd, DenovoMatrix GmbH, Percell Biolytica AB, and Asahi Kasei Corporation among others.

Buy Now-https://www.globalinsightservices.com/checkout/single_user/GIS20943

Research Scope

• Scope – Highlights, Trends, Insights. Attractiveness, Forecast
• Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others
• Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain
• Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments
• Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis
• Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis.

With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions

• In-depth segmentation which can be customized as per your requirements
• Free consultation with lead analyst of the report
• Infographic excel data pack, easy to analyze big data
• Robust and transparent research methodology
• Unmatched data quality and after sales service

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.